{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:07:54Z","timestamp":1793729274000,"version":"4.6.1"},"reference-count":142,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ajt.2022.11.013","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T18:05:46Z","timestamp":1673460346000},"page":"115-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Clinical recommendations for posttransplant assessment of anti\u2013HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6244-0795","authenticated-orcid":false,"given":"Carmen","family":"Lefaucheur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1766-2548","authenticated-orcid":false,"given":"Kevin","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-6370","authenticated-orcid":false,"given":"Anna B.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-046X","authenticated-orcid":false,"given":"Jean-Luc","family":"Taupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7393-7799","authenticated-orcid":false,"given":"Peter","family":"Nickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0320-9825","authenticated-orcid":false,"given":"Anat R.","family":"Tambur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-2752","authenticated-orcid":false,"given":"Howard M.","family":"Gebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3524-545X","authenticated-orcid":false,"given":"Elaine F.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-3172","authenticated-orcid":false,"given":"Jon A.","family":"Kobashigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9729-7717","authenticated-orcid":false,"given":"Anil","family":"Chandraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia P.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica M.","family":"Colvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-1937","authenticated-orcid":false,"given":"Ramsey R.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-2184","authenticated-orcid":false,"given":"Laurie D.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0638-2586","authenticated-orcid":false,"given":"Stuart C.","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1625-385X","authenticated-orcid":false,"given":"Stuart J.","family":"Knechtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-0922","authenticated-orcid":false,"given":"Jacqueline G.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Levitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41581-018-0039-x","article-title":"HLA in transplantation","volume":"14","author":"Montgomery","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1681\/ASN.2014080837","article-title":"Utility of HLA antibody testing in kidney transplantation","volume":"26","author":"Konvalinka","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.healun.2018.01.1291","article-title":"The management of antibodies in heart transplantation: an ISHLT consensus document","volume":"37","author":"Kobashigawa","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib6","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/ajt.14752","article-title":"Sensitization in transplantation: assessment of risk (STAR) 2017 working group meeting report","volume":"18","author":"Tambur","year":"2018","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib7","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1111\/ajt.15937","article-title":"Sensitization in transplantation: assessment of risk (STAR) 2019 working group meeting report","volume":"20","author":"Tambur","year":"2020","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib9","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell\u2013 and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib10","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/ajt.12287","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA","volume":"13","author":"Reed","year":"2013","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib11","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/ajt.15258","article-title":"Assessing the utilization of high-resolution 2-field HLA typing in solid organ transplantation","volume":"19","author":"Huang","year":"2019","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/tan.13619","volume":"94","author":"Smith","year":"2019","journal-title":"HLA"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib13","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1111\/ajt.15938","article-title":"Clinical importance of extended second field high-resolution HLA genotyping for kidney transplantation","volume":"20","author":"Senev","year":"2020","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib14","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1111\/ajt.14951","article-title":"Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation","volume":"18","author":"McCaughan","year":"2018","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib15","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1681\/ASN.2020010019","article-title":"Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: an observational cohort study","volume":"31","author":"Senev","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ajt.2022.11.013_bib16","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1111\/ajt.15414","article-title":"Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation","volume":"19","author":"Senev","year":"2019","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib17","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/ajt.14691","article-title":"Incidence, characterization, and impact of newly detected donor-specific anti-HLA antibody in the first year after pediatric heart transplantation: A report from the CTOTC-04 study","volume":"18","author":"Dipchand","year":"2018","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.healun.2020.09.003","article-title":"Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction","volume":"39","author":"Iasella","year":"2020","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib19","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/lt.25177","article-title":"Prevalence, risk factors, and impact of donor-specific alloantibodies after adult liver transplantation","volume":"24","author":"Vandevoorde","year":"2018","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.humimm.2018.02.014","article-title":"Impact of persistent and cleared preformed HLA DSA on kidney transplant outcomes","volume":"79","author":"Redondo-Pach\u00f3n","year":"2018","journal-title":"Hum Immunol"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib21","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1097\/TXD.0000000000000926","article-title":"Class and kinetics of weakly reactive pretransplant donor-specific HLA antibodies predict rejection in kidney transplant recipients","volume":"5","author":"Morrison","year":"2019","journal-title":"Transplant Direct"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib22","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/ndt\/gfy316","article-title":"A\u00a0paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival","volume":"34","author":"Michielsen","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib23","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/ajt.14709","article-title":"Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant","volume":"18","author":"Kamburova","year":"2018","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2215\/CJN.13401118","article-title":"Preformed donor-specific HLA antibodies in living and deceased donor transplantation: A multicenter study","volume":"14","author":"Ziemann","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ajt.15595","article-title":"Donor-specific antibodies detected by single antigen beads alone can help risk stratify patients undergoing retransplantation across a repeat HLA mismatch","volume":"20","author":"Lucisano","year":"2020","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib26","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/ajt.13795","article-title":"Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies","volume":"16","author":"Ferrandiz","year":"2016","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib27","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/ajt.15233","article-title":"Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation","volume":"19","author":"Hassan","year":"2019","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib28","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/ndt\/gfu208","article-title":"Pregnancy after kidney transplantation: outcome and anti-human leucocyte antigen alloimmunization risk","volume":"29","author":"Hebral","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/tan.14077","article-title":"Donor-specific HLA antibodies after fresh decellularized vs cryopreserved native allograft implantation","volume":"96","author":"Coti","year":"2020","journal-title":"HLA"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib30","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.kint.2018.12.029","article-title":"Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression","volume":"95","author":"Snanoudj","year":"2019","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib31","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.TP.0000110408.83054.88","article-title":"Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review","volume":"77","author":"Butler","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib32","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/TXD.0000000000000862","article-title":"High calcineurin inhibitor intrapatient variability is associated with renal allograft inflammation, chronicity, and graft loss","volume":"5","author":"Sharma","year":"2019","journal-title":"Transplant Direct"},{"issue":"11","key":"10.1016\/j.ajt.2022.11.013_bib33","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1681\/ASN.2017030287","article-title":"Class II eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development","volume":"28","author":"Wiebe","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/1744666X.2020.1693263","article-title":"Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients","volume":"15","author":"Mendoza Rojas","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib35","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1111\/ajt.15489","article-title":"The quest to decipher HLA immunogenicity: telling friend from foe","volume":"19","author":"Tambur","year":"2019","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ajt.16290","article-title":"Adequate tacrolimus exposure modulates\u00a0the\u00a0impact of HLA class II molecular mismatch: a validation study in an American cohort","volume":"21","author":"Davis","year":"2021","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib37","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1097\/TP.0000000000001012","article-title":"De novo anti-HLA DSA characteristics and subclinical antibody-mediated kidney allograft injury","volume":"100","author":"Yamamoto","year":"2016","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib38","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/ajt.14161","article-title":"The value of protocol biopsies\u00a0to\u00a0identify patients with de novo donor-specific antibody at high risk for allograft loss","volume":"17","author":"Schinstock","year":"2017","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib39","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1111\/ajt.14466","article-title":"Utility of protocol kidney biopsies for de novo donor-specific antibodies","volume":"17","author":"Parajuli","year":"2017","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib40","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/ajt.14015","article-title":"Evaluation of C1q status and titer of de novo donor-specific antibodies as predictors of allograft survival","volume":"17","author":"Wiebe","year":"2017","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib41","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1097\/TP.0000000000003055","article-title":"Protocol biopsies in patients with subclinical de novo donor-specific antibodies after kidney transplantation: A multicentric study","volume":"104","author":"Bertrand","year":"2020","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib42","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1681\/ASN.2016070797","article-title":"Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients","volume":"28","author":"Aubert","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.kint.2016.10.040","article-title":"Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent\/recurrent versus de novo donor-specific antibodies","volume":"91","author":"Haas","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.ajt.2022.11.013_bib44","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1600-6143.2009.02813.x","article-title":"Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies","volume":"9","author":"Loupy","year":"2009","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib45","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1681\/ASN.2013111149","article-title":"Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection","volume":"25","author":"Loupy","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ajt.2022.11.013_bib46","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1681\/ASN.2021040433","article-title":"Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection","volume":"32","author":"Madill-Thomsen","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.trre.2018.05.002","article-title":"The clinical impact of donor-specific antibodies in heart transplantation","volume":"32","author":"Barten","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.TP.0000436927.08026.a8","article-title":"Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome","volume":"97","author":"Reinsmoen","year":"2014","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/tri.12684","article-title":"Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance","volume":"29","author":"Svobodova","year":"2016","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.healun.2016.10.016","article-title":"Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation","volume":"36","author":"Clerkin","year":"2017","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib51","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/ajt.14876","article-title":"Pediatric heart transplantation across a positive crossmatch: first year results from the CTOTC-04 multi-institutional study","volume":"18","author":"Webber","year":"2018","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib52","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.healun.2015.05.001","article-title":"Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation","volume":"34","author":"Irving","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"11","key":"10.1016\/j.ajt.2022.11.013_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13416","article-title":"De novo donor-specific HLA antibodies in heart transplantation: Do transient de novo DSA confer the same risk as persistent de novo DSA?","volume":"32","author":"Moayedi","year":"2018","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.healun.2017.11.003","article-title":"Racial differences in the development of de-novo donor-specific antibodies and treated antibody-mediated rejection after heart transplantation","volume":"37","author":"Cole","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib55","first-page":"330","article-title":"HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients","volume":"81","author":"Zhang","year":"2020","journal-title":"Hum\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib56","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healun.2015.10.006","article-title":"The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children","volume":"35","author":"Ware","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib57","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1097\/TP.0000000000002333","article-title":"Understanding the correlation between DSA, complement activation, and antibody-mediated rejection in heart transplant recipients","volume":"102","author":"Zhang","year":"2018","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.healun.2015.08.008","article-title":"Donor-specific HLA alloantibodies: impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation","volume":"35","author":"Tran","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib59","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/TP.0000000000001944","article-title":"Complement (C1q) binding de novo donor-specific antibodies and cardiac-allograft vasculopathy in pediatric heart transplant recipients","volume":"102","author":"Das","year":"2018","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.healun.2015.10.013","article-title":"Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens","volume":"35","author":"Reinsmoen","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib61","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.healun.2014.07.012","article-title":"De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation","volume":"33","author":"Safavi","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib62","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.healun.2016.05.020","article-title":"De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome","volume":"35","author":"Le Pavec","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib63","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01898-2017","article-title":"Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome","volume":"52","author":"Brugi\u00e8re","year":"2018","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib64","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1164\/rccm.201509-1857OC","article-title":"De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation","volume":"194","author":"Tikkanen","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib65","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.healun.2014.06.015","article-title":"Early donor-specific antibodies in lung transplantation: risk factors and impact on survival","volume":"33","author":"Ius","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib66","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.healun.2014.07.018","article-title":"De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation","volume":"33","author":"Morrell","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.healun.2014.09.019","article-title":"Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation","volume":"34","author":"Ius","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib68","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/ajt.15687","article-title":"Pseudomonas aeruginosa and acute rejection independently increase the risk of donor-specific antibodies after lung transplantation","volume":"20","author":"Kulkarni","year":"2020","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib69","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.healun.2018.01.1305","article-title":"Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: evidence from cell-free DNA analysis","volume":"37","author":"Agbor-Enoh","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib70","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.healun.2014.02.033","article-title":"Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation","volume":"33","author":"Smith","year":"2014","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib71","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1513\/AnnalsATS.201812-869OC","article-title":"Clinical outcomes of lung transplantation in the presence of donor-specific antibodies","volume":"16","author":"Courtwright","year":"2019","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib72","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14893","article-title":"Human leukocyte antigens antibodies after lung transplantation: primary results of the HALT study","volume":"18","author":"Hachem","year":"2018","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib73","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01248-2017","article-title":"Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation","volume":"50","author":"Verleden","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ajt.2022.11.013_bib74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fmed.2017.00155","article-title":"Characteristics of donor-specific antibodies associated with antibody-mediated rejection in lung transplantation","volume":"4","author":"Roux","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ajt.2022.11.013_bib75","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/972705","article-title":"Significance of semiquantitative assessment of preformed donor-specific antibody using Luminex single bead assay in living related liver transplantation","volume":"2013","author":"Yoshizawa","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib76","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/ctr.12851","article-title":"Preformed donor-specific HLA antibodies are associated with increased risk of early mortality after liver transplantation","volume":"30","author":"McCaughan","year":"2016","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4174\/astr.2015.88.2.100","article-title":"Effect of donor-specific antibodies and panel reactive antibodies in living donor liver transplant recipients","volume":"88","author":"Song","year":"2015","journal-title":"Ann Surg Treat Res"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib78","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/lt.25663","article-title":"Outcome of liver transplant patients with preformed donor-specific anti-human leukocyte antigen antibodies","volume":"26","author":"Del Bello","year":"2020","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib79","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13244","article-title":"Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation","volume":"32","author":"Kim","year":"2018","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib80","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1097\/TXD.0000000000001180","article-title":"Rituximab desensitization in liver transplant recipients with preformed donor-specific HLA antibodies: A Japanese nationwide survey","volume":"7","author":"Akamatsu","year":"2021","journal-title":"Transplant Direct"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib81","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.23687","article-title":"Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation","volume":"19","author":"O\u2019Leary","year":"2013","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib82","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/tri.13763","article-title":"De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation \u2013 a retrospective study","volume":"33","author":"Kovandova","year":"2020","journal-title":"Transpl Int"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib83","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/ajt.13757","article-title":"Donor-specific HLA antibodies in living versus deceased donor liver transplant recipients","volume":"16","author":"Levitsky","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2022.11.013_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.613128","article-title":"De novo donor specific antibody and long-term outcome after liver transplantation: A systematic review and meta-analysis","volume":"11","author":"Beyzaei","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib85","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70938-7","article-title":"Non-invasive screening for subclinical liver graft injury in adults via donor-specific anti-HLA antibodies","volume":"10","author":"H\u00f6fer","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/TP.0000000000003649","article-title":"Evaluation of graft fibrosis, inflammation and donor-specific antibodies at protocol liver biopsies in pediatric liver transplant patients: a single center experience","volume":"106","author":"Pinon","year":"2022","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib87","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/lt.25187","article-title":"Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients","volume":"24","author":"Dao","year":"2018","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib88","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/TP.0000000000003099","article-title":"Peripheral donor-specific antibodies are associated with histology and cellular subtypes in protocol liver biopsies of pediatric recipients","volume":"104","author":"Cousin","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.ajt.2022.11.013_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2020.101306","article-title":"Predictive value of HLAMatchmaker and PIRCHE-II scores for de novo donor-specific antibody formation after adult and pediatric liver transplantation","volume":"61","author":"Hamada","year":"2020","journal-title":"Transpl Immunol"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib90","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/hep.28681","article-title":"Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R","volume":"65","author":"Feng","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib91","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/hep.30281","article-title":"Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients","volume":"69","author":"Jucaud","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib92","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib93","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/tri.13874","article-title":"Stratifying the humoral risk of candidates to a solid organ transplantation: a proposal of the ENGAGE working group","volume":"34","author":"Bestard","year":"2021","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib94","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ajt.14112","article-title":"The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: improving antibody-mediated rejection diagnostics: strengths, unmet needs, and future directions","volume":"17","author":"Bruneval","year":"2017","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ajt.14990","article-title":"Banff Lung Report: current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR)","volume":"19","author":"Roux","year":"2019","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib96","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 Comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib97","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2021.04.044","article-title":"The emerging field of non-human leukocyte antigen antibodies in transplant medicine and beyond","volume":"100","author":"Lefaucheur","year":"2021","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib98","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1681\/ASN.2020030306","article-title":"Transcriptional changes in kidney allografts with histology of antibody-mediated rejection without anti-HLA donor-specific antibodies","volume":"31","author":"Callemeyn","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib99","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/ajt.15074","article-title":"Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome","volume":"19","author":"Senev","year":"2019","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib100","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/ajt.15171","article-title":"Refinement of humoral rejection effector mechanisms to identify specific pathogenic histological lesions with different graft outcomes","volume":"19","author":"Bestard","year":"2019","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib101","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1111\/ajt.17092","article-title":"Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes","volume":"22","author":"Halloran","year":"2022","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib102","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.2215\/CJN.04230320","article-title":"The histological picture of indication biopsies in the first 2 weeks after kidney transplantation","volume":"15","author":"Van Loon","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib103","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1038\/s41467-019-13113-5","article-title":"Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants","volume":"10","author":"Koenig","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib104","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2014111120","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury","volume":"27","author":"Lefaucheur","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib105","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/ajt.16904","article-title":"IgG3 donor-specific antibodies with a proinflammatory glycosylation profile may be associated with the risk of antibody-mediated rejection after kidney transplantation","volume":"22","author":"Pernin","year":"2022","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib106","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1681\/ASN.2017070749","article-title":"Dynamic prognostic score to predict kidney allograft survival in patients with antibody-mediated rejection","volume":"29","author":"Viglietti","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib107","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib108","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib109","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/TP.0000000000002002","article-title":"Prognostic value of the persistence of C1q-binding anti-HLA antibodies in acute antibody-mediated rejection in kidney transplantation","volume":"102","author":"Bailly","year":"2018","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib110","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.kint.2018.03.015","article-title":"Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection","volume":"94","author":"Viglietti","year":"2018","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib111","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.healun.2013.08.011","article-title":"The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation","volume":"32","author":"Berry","year":"2013","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib112","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1111\/ajt.15863","article-title":"Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: from bench to bedside","volume":"20","author":"Butler","year":"2020","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib113","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/ajt.16420","article-title":"Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients","volume":"21","author":"Patel","year":"2021","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib114","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.healun.2016.01.1223","article-title":"Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation","volume":"35","author":"Levine","year":"2016","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib115","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/ajt.14222","article-title":"Proteasome inhibitor carfilzomib-based therapy for antibody-mediated rejection of the pulmonary allograft: use and short-term findings","volume":"17","author":"Ensor","year":"2017","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib116","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1097\/TXD.0000000000001131","article-title":"Assessment of carfilzomib treatment response in lung transplant recipients with antibody-mediated rejection","volume":"7","author":"Pham","year":"2021","journal-title":"Transplant Direct"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib117","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/tri.13825","article-title":"Guiding therapeutic plasma exchange for antibody-mediated rejection treatment in lung transplant recipients \u2013 a retrospective study","volume":"34","author":"Timofeeva","year":"2021","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib118","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/ajt.13476","article-title":"Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts","volume":"16","author":"O\u2019Leary","year":"2016","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib119","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1097\/TP.0000000000001802","article-title":"Chronic AMR in liver transplant: validation of the 1-year cAMR score\u2019s ability to determine long-term outcome","volume":"101","author":"O\u2019Leary","year":"2017","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOT.0000000000000275","article-title":"Prevention and treatment of liver allograft antibody-mediated rejection and the role of the \u201ctwo-hit hypothesis","volume":"21","author":"Kim","year":"2016","journal-title":"Curr Opin Organ Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOT.0000000000000719","article-title":"Rethinking clinical endpoints in kidney transplant trials","volume":"25","author":"Maggiore","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"issue":"12","key":"10.1016\/j.ajt.2022.11.013_bib122","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1681\/ASN.2012070664","article-title":"Donor-specific antibodies adversely affect kidney allograft outcomes","volume":"23","author":"Mohan","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib123","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.2016030368","article-title":"Value of donor-specific anti-HLA antibody monitoring and characterization for risk stratification of kidney allograft loss","volume":"28","author":"Viglietti","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ajt.2022.11.013_bib124","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfy349","article-title":"Positive Luminex and negative flow cytometry in kidney transplantation: a systematic review and meta-analysis","volume":"34","author":"Buttigieg","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib125","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/ajt.13295","article-title":"Assessing antibody strength: comparison of MFI, C1q, and titer information","volume":"15","author":"Tambur","year":"2015","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib126","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MOT.0000000000000659","article-title":"A\u00a0diagnostic \u201cC\u201d saw: the ups and downs of C1q testing","volume":"24","author":"Gebel","year":"2019","journal-title":"Curr Opin Organ Transplant"},{"issue":"3","key":"10.1016\/j.ajt.2022.11.013_bib127","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/ajt.16363","article-title":"Estimating alloantibody levels in highly sensitized renal allograft candidates: using serial dilutions to demonstrate a treatment effect in clinical trials","volume":"21","author":"Tambur","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ajt.2022.11.013_bib128","doi-asserted-by":"crossref","first-page":"l4923","DOI":"10.1136\/bmj.l4923","article-title":"Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study","volume":"366","author":"Loupy","year":"2019","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib129","doi-asserted-by":"crossref","first-page":"e052138","DOI":"10.1136\/bmjopen-2021-052138","article-title":"Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study","volume":"11","author":"Aubert","year":"2021","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.ajt.2022.11.013_bib130","doi-asserted-by":"crossref","first-page":"e1002572","DOI":"10.1371\/journal.pmed.1002572","article-title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis","volume":"15","author":"Bouquegneau","year":"2018","journal-title":"PLOS Med"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib131","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/ndt\/gfw445","article-title":"Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen","volume":"32","author":"Zecher","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajt.13529","article-title":"Late failing heart allografts: pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection","volume":"16","author":"Loupy","year":"2016","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.ajt.2022.11.013_bib133","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.healun.2015.03.002","article-title":"Late antibody-mediated rejection after heart transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy","volume":"34","author":"Coutance","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"24","key":"10.1016\/j.ajt.2022.11.013_bib134","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/CIRCULATIONAHA.119.044924","article-title":"Identification and characterization of trajectories of cardiac allograft vasculopathy after heart transplantation: a population-based study","volume":"141","author":"Loupy","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ajt.2022.11.013_bib135","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/tri.13149","article-title":"Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study","volume":"31","author":"Roux","year":"2018","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.ajt.2022.11.013_bib136","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1053\/j.gastro.2018.08.023","article-title":"Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants","volume":"155","author":"Feng","year":"2018","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.ajt.2022.11.013_bib137","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1097\/TP.0000000000000613","article-title":"Donor-specific anti-HLA antibodies and endothelial C4d deposition-association with chronic liver allograft failure","volume":"99","author":"Iacob","year":"2015","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.ajt.2022.11.013_bib138","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/lt.23948","article-title":"Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features","volume":"20","author":"O\u2019Leary","year":"2014","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.ajt.2022.11.013_bib139","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/ajt.12651","article-title":"Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients","volume":"14","author":"Del Bello","year":"2014","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.ajt.2022.11.013_bib140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/ajt.15621","article-title":"IgG4 donor-specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients","volume":"20","author":"Jackson","year":"2020","journal-title":"Am J Transplant"},{"issue":"suppl 2","key":"10.1016\/j.ajt.2022.11.013_bib141","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/tan.13354","article-title":"Antibody-mediated rejection after liver transplantation-relevance of C1q and C3d-binding antibodies","volume":"92","author":"Kovandova","year":"2018","journal-title":"HLA"},{"issue":"1","key":"10.1016\/j.ajt.2022.11.013_bib142","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/TP.0000000000001887","article-title":"Terasaki epitope mismatch burden predicts the development of de novo DQ donor-specific antibodies and are associated with adverse allograft outcomes","volume":"102","author":"Willicombe","year":"2018","journal-title":"Transplantation"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522272529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522272529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:34:22Z","timestamp":1761629662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522272529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":142,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1600613522272529"],"URL":"https:\/\/doi.org\/10.1016\/j.ajt.2022.11.013","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical recommendations for posttransplant assessment of anti\u2013HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajt.2022.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of American Society of Transplantation & American Society of Transplant Surgeons.","name":"copyright","label":"Copyright"}]}}